bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures 1 - 5 from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Authors: Baek Sora , Choi Chang-Min , Ahn Sei Hyun , Lee Jong Won , Gong Gyungyub , Ryu Jin-Sook , Oh Seung Jun , Bacher-Stier Claudia , Fels Lüder , Koglin Norman , Hultsch Christina , Schatz Christoph A. , Dinkelborg Ludger M. , Mittra Erik S. , Gambhir Sanjiv S. , Moon Dae Hyuk
Published: April 2023

PDF file, 358K, S1: System xC� and CD44 in glutathione biosynthesis and the cysteine-cystine redox cycle; S2: 18FFSPG distribution in normal organs and cancer; S3: Correlation between 18FFDG and 18FFSPG; S4: 18FFDG and 18FFSPG PET in a breast cancer patient; S5: Correlation analysis between the staining intensity of xC� transporter and CD44 expression.
Supplementary Table 3 from Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization
Authors: Kim Beom Kyung , Kim Seung Up , Kim Myeong-Jin , Kim Kyung Ah , Kim Do Young , Park Jun Yong , Ahn Sang Hoon , Han Kwang-Hyub , Chon Chae Yoon
Published: April 2023

PDF file - 111K, Detailed agreement rates in subgroups according to tumor numbers
CCR Translation for This Article from Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization
Authors: Kim Beom Kyung , Kim Seung Up , Kim Myeong-Jin , Kim Kyung Ah , Kim Do Young , Park Jun Yong , Ahn Sang Hoon , Han Kwang-Hyub , Chon Chae Yoon
Published: April 2023

CCR Translation for This Article from Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization
Supplementary Figures 7 - 14, Tables 3 - 7 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma
Authors: Riester Markus , Werner Lillian , Bellmunt Joaquim , Selvarajah Shamini , Guancial Elizabeth A. , Weir Barbara A. , Stack Edward C. , Park Rachel S. , O'Brien Robert , Schutz Fabio A.B. , Choueiri Toni K. , Signoretti Sabina , Lloreta Josep , Marchionni Luigi , Gallardo Enrique , Rojo Federico , Garcia Denise I. , Chekaluk Yvonne , Kwiatkowski David J. , Bochner Bernard H. , Hahn William C. , Ligon Azra H. , Barletta Justine A. , Loda Massimo , Berman David M. , Kantoff Philip W. , Michor Franziska , Rosenberg Jonathan E.
Published: April 2023

PDF file - 310KB, Figure S7: Comparison of copy number ratios at the 1q21.2 (MCL1) locus and 1q23.3; Figure S8: IGV screenshots of the 1q23.3 amplified region (Figure 3) for both cohorts; Figure S9: Kaplan-Meier curves for the second 1q23.3 GISTIC peak, located around FCGR3B; Figure S10: Kaplan-Meier curves for the PBX1 GISTIC peak at 1q23.3 (peak 3); Figure S11: Venn diagram of patients with amplification (log2 > 0.9) of the three GISTIC peaks in the (a) Spanish, (b) DFCI and (c) TCGA cohorts; Figure S12: Boxplots visualizing the correlation of mRNA expression and copy number in the Spanish cohort for all genes in the 1q23.3 GISTIC peak 1; Figure S13: Boxplots visualizing the correlation of mRNA expression and copy number in the DFCI cohort for all genes in the 1q23.3 GISTIC peak 1; Figure S14: Panel (a) shows the correlation of copy number and Immunohistochemistry (IHC) staining of the PVRL4 gene in the Spanish cohort; Table S3: Associations of GISTIC peaks with overall survival after start of chemotherapy, adjusted for ECOG performance status and visceral disease (Spanish cohort); Table S4: Copy numbers in all bladder cancer cohorts at all three 1q23.3 GISTIC peaks. Numbers of patients in the TCGA cohort correspond to patients with clinical information; Table S5: Associations of ECOG PS, visceral disease, 1q23.3 amplification (peak 2, FCGR3B gene) and OS; Table S6: Associations of ECOG PS, visceral disease, 1q23.3 amplification (peak 3, PBX1 gene) and OS; Table S7: For the genes in 1q23.3, this table lists the correlations of copy number and mRNA expression and the correlations of overall survival and mRNA expression.
Supplementary Table S2 from Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing
Authors: Buttitta Fiamma , Felicioni Lara , Del Grammastro Maela , Filice Giampaolo , Di Lorito Alessia , Malatesta Sara , Viola Patrizia , Centi Irene , D'Antuono Tommaso , Zappacosta Roberta , Rosini Sandra , Cuccurullo Franco , Marchetti Antonio
Published: April 2023

PDF file - 92K,EGFR-positive controls samples (C1-C5) and bronchoalveolar lavage and pleura fluids samples found to be negative for EGFR mutations by Sanger sequencing and next generation sequencing analysis. Comparison with EGFR mutations by Sanger sequencing on matched surgical samples
Supplementary Table S1 from Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing
Authors: Buttitta Fiamma , Felicioni Lara , Del Grammastro Maela , Filice Giampaolo , Di Lorito Alessia , Malatesta Sara , Viola Patrizia , Centi Irene , D'Antuono Tommaso , Zappacosta Roberta , Rosini Sandra , Cuccurullo Franco , Marchetti Antonio
Published: April 2023

PDF file - 99K,List of forward and reverse fusion primers utilized for PCR amplification of EGFR exon 19 and 21
Supplementary Figure 2 from Relationship of Mammographic Density and Gene Expression: Analysis of Normal Breast Tissue Surrounding Breast Cancer
Authors: Sun Xuezheng , Gierach Gretchen L. , Sandhu Rupninder , Williams Tyisha , Midkiff Bentley R. , Lissowska Jolanta , Wesolowska Ewa , Boyd Norman F. , Johnson Nicole B. , Figueroa Jonine D. , Sherman Mark E. , Troester Melissa A.
Published: April 2023

Supplementary Figure 2 - PDF file 138KB, The Creighton method to evaluate the association of gene expression profile of each patient with pre-defined biological signatures
Supplementary Figure 3 from Myeloid Differentiation Factor 88 Promotes Growth and Metastasis of Human Hepatocellular Carcinoma
Authors: Liang Beibei , Chen Rui , Wang Tao , Cao Lei , Liu Yingying , Yin Fan , Zhu Minhui , Fan Xiaoyu , Liang Yingchao , Zhang Lu , Guo Yajun , Zhao Jian
Published: April 2023

PDF File - 868K, MyD88 regulated the expression of several tumor modifiers in HCC-LM3 cells. And inhibition of PI3K/Akt, p38 and MEK-ERK pathway decreased NF-�B signal activities upregulated by overexpressing MyD88 in HCC-LM3 as analyzed by the luciferase activities.
Supplementary Table 4 from Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy
Authors: Beard Rachel E. , Abate-Daga Daniel , Rosati Shannon F. , Zheng Zhili , Wunderlich John R. , Rosenberg Steven A. , Morgan Richard A.
Published: April 2023

XLSX file - 64K, Supplemental Table S4. Normal Tissues: Brain Brainstem Eye Skin Trachea Salivary Artery Vein Heart Lung.
Supplementary Table 3 from Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy
Authors: Beard Rachel E. , Abate-Daga Daniel , Rosati Shannon F. , Zheng Zhili , Wunderlich John R. , Rosenberg Steven A. , Morgan Richard A.
Published: April 2023

XLSX file - 93K, Supplemental Table S3. TUMORS: 1 2 3 4 5 6 MELANOMA RELATED GENES.
Supplementary Figure 1 from Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models
Authors: Zhang Jingchuan , Zhang Lin , Su Xinying , Li Ming , Xie Liang , Malchers Florian , Fan ShuQiong , Yin XiaoLu , Xu YanPing , Liu Kunji , Dong Zhengwei , Zhu Guanshan , Qian Ziliang , Tang Lili , Zhan Ping , Ji Qunsheng , Kilgour Elaine , Smith Paul D. , Brooks A. Nigel , Thomas Roman K. , Gavine Paul R.
Published: April 2023

PDF file - 219K, AZD4547 demonstrates potent anti-tumor efficacy in the standard FGFR1-amplified xenograft lung model, NCI-H1581
Supplementary Methods, Tables 1 - 2, Figures 1 - 2 from Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
Authors: Leijen Suzanne , Middleton Mark R. , Tresca Patricia , Kraeber-Bodéré Françoise , Dieras Veronique , Scheulen Max E. , Gupta Avinash , Lopez-Valverde Vanesa , Xu Zhi-Xin , Rueger Ruediger , Tessier Jean J.L. , Shochat Eliezer , Blotner Steve , Naegelen Valerie Meresse , Schellens Jan H.M. , Eberhardt Wilfried Ernst Erich
Published: April 2023

PDF file, 1001K, Methods; Supplementary Table 1 - Temporary dose interruptions due to adverse events; Supplementary Table 2 - Changes in biomarker levels between baseline and Day 15; Supplementary Figure 1: Schematic showing dosing cohorts, DLTs and the MTD; Supplementary Figure 2 - Case-study: FDG-PET uptake at baseline.
Supplementary Figure 2 from Downregulation of miR-452 Promotes Stem-Like Traits and Tumorigenicity of Gliomas
Authors: Liu Liping , Chen Kun , Wu Jueheng , Shi Ling , Hu Bo , Cheng Shiyuan , Li Mengfeng , Song Libing
Published: April 2023

Overexpression of miR-452 reduces glioma stem-like traits.
Supplementary Figure 1 from Genetic Variations Associated with Postoperative Recurrence in Stage I Non–Small Cell Lung Cancer
Authors: Yoon Kyong-Ah , Jung Mee Kyung , Lee Donghoon , Bae Kieun , Joo Jung Nam , Lee Geon Kook , Lee Hyun-Sung , Lee Jin Soo
Published: April 2023

PDF - 2465K, Manhattan plot is used to evaluate the overall significance of the GWAS data using a trend p-value plot across the genome (A). Quantile-quantile plot is shown with the measured genetic inflation factor to reveal minimal overall inflation of the association results (B).
Supplementary Figure 1 from Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy
Authors: Zhao Jun , Ma Mark Z. , Ren Hening , Liu Zhenqiu , Edelman Martin J. , Pan Hong , Mao Li
Published: April 2023

Supplementary Figure 1 - PDF file 92K, A, Fold changes of the 84 stem-cell related genes after treated with bevacizumab + chemotherapy (Arm A) in the tumor models MDA2131-5 and MDA2131-8. The genes are arranged based on fold changes from the most down-regulated to the most up-regulated from left to right horizontally. B, Fold changes of the 84 stem-cell related genes after treated with HDGF-H3 + chemotherapy (Arm D) in the tumor models MDA2131-5 and MDA2131-8. The genes are arranged based on fold changes from the most down-regulated to the most up-regulated from left to right horizontally.
Supplementary Figure 5 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein
Authors: Reis Bernardo Sgarbi , Jungbluth Achim A. , Frosina Denise , Holz Megan , Ritter Erika , Nakayama Eiichi , Ishida Toshiaki , Obata Yuichi , Carver Brett , Scher Howard , Scardino Peter T. , Slovin Susan , Subudhi Sumit K. , Reuter Victor E. , Savage Caroline , Allison James P. , Melamed Jonathan , Jäger Elke , Ritter Gerd , Old Lloyd J. , Gnjatic Sacha
Published: April 2023

- PDF file 63K, Correlation between antibodies against GAG-HERV-K and group risk or Gleason score in cancer patients. Prostate cancer patients were split (A) in 3 groups according to Gleason score and classified from group risk 1 to 3 and compared to healthy donors (HD), or (B) in 3 groups according to Gleason score as indicated. Antibodies anti-GAG-HERV-K were detected and analyzed as in Fig. 4. Asterisk denotes significantly higher frequency of seropositive patients (titer > 100) in risk group 3 and Gleason {greater than or equal to} 8 (Chi-square test, p<0.003)
Supplementary Figure 4 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein
Authors: Reis Bernardo Sgarbi , Jungbluth Achim A. , Frosina Denise , Holz Megan , Ritter Erika , Nakayama Eiichi , Ishida Toshiaki , Obata Yuichi , Carver Brett , Scher Howard , Scardino Peter T. , Slovin Susan , Subudhi Sumit K. , Reuter Victor E. , Savage Caroline , Allison James P. , Melamed Jonathan , Jäger Elke , Ritter Gerd , Old Lloyd J. , Gnjatic Sacha
Published: April 2023

- PDF file 418K, Characterization of TI-35 mAb by subcellular colocalization of staining with GAG-HERV-K expression and by transfection. A-B, Confocal images of HeLa cells transfected with GAG-HERV-K_GFP (A) or GFP only (B) and stained with TI-35. Blue represents DAPI nuclear staining, green represents GFP, and purple represents TI-35 staining. Colocalization is observed in the merged data as white, in areas indicated by arrows. Axes in the corner of each quadrant show size/magnification information. C-D, TI-35 immunostaining with formalin-fixed Sf9 insect cells infected with GAG-HERV-K-recombinant baculovirus (C) or control baculovirus (D). Original magnification (objective) was 4x, and insets show zoomed area at 20x
Supplementary Figure 3 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein
Authors: Reis Bernardo Sgarbi , Jungbluth Achim A. , Frosina Denise , Holz Megan , Ritter Erika , Nakayama Eiichi , Ishida Toshiaki , Obata Yuichi , Carver Brett , Scher Howard , Scardino Peter T. , Slovin Susan , Subudhi Sumit K. , Reuter Victor E. , Savage Caroline , Allison James P. , Melamed Jonathan , Jäger Elke , Ritter Gerd , Old Lloyd J. , Gnjatic Sacha
Published: April 2023

- PDF file 204K, Alignment of GAG proteins derived from human endogenous retroviruses and respective epitopes recognized by prostate cancer patient sera. A, Detail alignment from several GAG-HERV-K family members and the TI-35 binding site (red) highlighting the amino-acid differences present in GAG-HERV-K ch22q11.23 (blue). B, Western-blot analysis of immunoprecipitation of GAG-HERV-K from VCaP and LNCaP prostate cancer cell lines. WFP prostate cancer patient serum (WFP) was incubated with VCaP or LNCaP protein extract for 2 hours at 4{degrees}C. Protein-antibody complexes were pulled down using anti-human IgG sepharose beads. The pull-down pellet was submitted to SDS-PAGE and Western-blot analysis. Reactivity to GAG-HERV-K protein was developed by incubating the membrane with TI-35 monoclonal antibody. A pool of healthy donor sera was used as control (Con). C, Summary of ELISA results from epitope mapping using 20mers peptides overlapping by 10aa (71 peptides tested in total from JPT Innovative Peptide Solution, Berlin, Germany) spanning GAG-HERV-K and tested individually for recognition by monoclonal antibody TI-35 and different prostate cancer patient sera seropositive for GAG-HERV-K protein. The square symbol represents a positive reaction to the corresponding peptide (labeled by aminoacid start and end position). A pool of healthy donor sera was used as control (Con pool). Plates were coated with 5 uM peptide and the reaction was performed as previously described in methods
Supplementary Table 3a from AIB1:ERα Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor–Resistant Breast Cancer Cells
Authors: O'Hara Jane , Vareslija Damir , McBryan Jean , Bane Fiona , Tibbitts Paul , Byrne Christopher , Conroy Ronán M. , Hao Yuan , Gaora Peadar Ó , Hill Arnold D.K. , McIlroy Marie , Young Leonie S.
Published: April 2023

PDF file, 365KB, Supplementary Table 3a ER/AIB1 overlap genelist - full ERE.
Supplementary Table 1 from AIB1:ERα Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor–Resistant Breast Cancer Cells
Authors: O'Hara Jane , Vareslija Damir , McBryan Jean , Bane Fiona , Tibbitts Paul , Byrne Christopher , Conroy Ronán M. , Hao Yuan , Gaora Peadar Ó , Hill Arnold D.K. , McIlroy Marie , Young Leonie S.
Published: April 2023

PDF file, 14KB, Supplementary Table 1: Demographics of patients according to AIB1 status.
Supplementary Table S1 from Aberrant Presentation of HPA-Reactive Carbohydrates Implies Selectin-Independent Metastasis Formation in Human Prostate Cancer
Authors: Lange Tobias , Kupfernagel Mareike , Wicklein Daniel , Gebauer Florian , Maar Hanna , Brügge Kathrin , Müller Imke , Simon Ronald , Schlomm Thorsten , Sauter Guido , Schumacher Udo
Published: April 2023

PDF file 53K, Summary of key characteristics and derivation of internal control cell lines and primary cells used in the present study
Supplementary Table 2 from Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy
Authors: Mortland Leslie , Alonzo Todd A. , Walter Roland B. , Gerbing Robert B. , Mitra Amit K. , Pollard Jessica A. , Loken Michael R. , Hirsch Betsy , Raimondi Susana , Franklin Janet , Pounds Stanley , Cao Xueyuan , Rubnitz Jeffrey E. , Ribeiro Raul C. , Gamis Alan , Meshinchi Soheil , Lamba Jatinder K.
Published: April 2023

Supplementary Table 2. Characteristics of pediatric AML patients treated on St. Jude AML02 trial.
Supplementary Figure S2 from Aberrant Presentation of HPA-Reactive Carbohydrates Implies Selectin-Independent Metastasis Formation in Human Prostate Cancer
Authors: Lange Tobias , Kupfernagel Mareike , Wicklein Daniel , Gebauer Florian , Maar Hanna , Brügge Kathrin , Müller Imke , Simon Ronald , Schlomm Thorsten , Sauter Guido , Schumacher Udo
Published: April 2023

PDF file 76K, Intrastromal PC-3 lung metastatic cells in E-/P-selectin-/- mice
Supplementary Table 1 from Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy
Authors: Mortland Leslie , Alonzo Todd A. , Walter Roland B. , Gerbing Robert B. , Mitra Amit K. , Pollard Jessica A. , Loken Michael R. , Hirsch Betsy , Raimondi Susana , Franklin Janet , Pounds Stanley , Cao Xueyuan , Rubnitz Jeffrey E. , Ribeiro Raul C. , Gamis Alan , Meshinchi Soheil , Lamba Jatinder K.
Published: April 2023

Supplementary Table 1. Characteristics of pediatric AML patients treated on AAML03P1 trial by four CD33 SNPs
Supplementary Figures from Protein Kinase C-δ–Mediated Recycling of Active KIT in Colon Cancer
Authors: Park Misun , Kim Won Kyu , Song Meiying , Park Minhee , Kim Hyunki , Nam Hye Jin , Baek Sung Hee , Kim Hoguen
Published: April 2023

PDF file, 779K, Figure S1. Expressionofp-KIT,p-AKT,andp-ERK increased according to the increased SCF concentrationin two KIT-expressingcelllines. Figure S2. Expression of KIT, p-KIT, p-AKT, and p-ERK after SCF treatment in two tumor cell lines with KIT mutation. FigureS3.Quantification of Westernblotting results for Fig.1E. FigureS4. Membranous KITexpression of DLD-1 was determined by FACS. Figure S5. Mutant KIT is not degraded after SCF treatment. Figure S6. FACS analysis of p-AKT and p-ERK expressing colon cancer cells treated with SCF and PMA. Figure S7. FACS analysis of KIT expression in the DLD-1 cells transfectedwith wild-type (Rab11-WT) or dominant-negative mutant form of Rab11 (Rab11-S25N). Figure S8. Effects of imatinibon CRC cells expressing KIT. FigureS9. DLD-1 cell number and invasion were increased after SCF and PMA treatment. FigureS10. Expression of SCF mRNA expression in CRC cell lines. Figure S11.Colon cancers expressing WT-KIT constantly generated activated KIT-SCF signaling as a result of KIT recycling in a condition of endogenous PKC-delta activation.
Supplementary Table 2 from Potentially Prognostic miRNAs in HPV-Associated Oropharyngeal Carcinoma
Authors: Hui Angela B.Y. , Lin Alice , Xu Wei , Waldron Levi , Perez-Ordonez Bayardo , Weinreb Ilan , Shi Wei , Bruce Jeff , Huang Shao Hui , O'Sullivan Brian , Waldron John , Gullane Patrick , Irish Jonathan C. , Chan Kelvin , Liu Fei-Fei
Published: April 2023

PDF file - 27K, MiRNAs associated with p16 in OPCs samples
Supplemental Table 1 from Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy
Authors: Bid Hemant K. , London Cheryl A. , Gao Jin , Zhong Haihong , Hollingsworth Robert E. , Fernandez Soledad , Mo Xiaokui , Houghton Peter J.
Published: April 2023

Supplemental Table 1 PDF file 56K, Comparisons of time-to-event curves for single or combined antibody therapy against pediatric sarcoma xenografts (listed are adjusted p-values)
Supplemental Figure 4 from Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy
Authors: Bid Hemant K. , London Cheryl A. , Gao Jin , Zhong Haihong , Hollingsworth Robert E. , Fernandez Soledad , Mo Xiaokui , Houghton Peter J.
Published: April 2023

Supplemental Figure 4 PDF file 103K,Histogram
Supplemental Figure 1 from Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy
Authors: Bid Hemant K. , London Cheryl A. , Gao Jin , Zhong Haihong , Hollingsworth Robert E. , Fernandez Soledad , Mo Xiaokui , Houghton Peter J.
Published: April 2023

Supplemental Figure 1 PDF file 151K, Photomicrograph. IGF-2 circumvents CP01-B02 antibody in vivo
Supplementary Tables 1 - 9 from Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting PIK3CD and Predicts the Prognosis of Human Glioblastoma
Authors: Shi Yu , Chen Cong , Zhang Xia , Liu Qing , Xu Jin-Ling , Zhang Hua-Rong , Yao Xiao-Hong , Jiang Tao , He Zhi-Cheng , Ren Yong , Cui Wei , Xu Chuan , Liu Ling , Cui You-Hong , Yu Shi-Zhu , Ping Yi-Fang , Bian Xiu-Wu
Published: April 2023

PDF file - 169K, Supplementary Table S1. The clinical features of the glioma specimens used in this study. Supplementary Table S2. Primers used for qRT-PCT, miRNA cloning and luciferase plasmid construction. Supplementary Table S3. Top 20 downregulated miRNAs in tumor tissue (GBM-T) versus adjacent normal tissue (GBM-N). Supplementary Table S4. Top 20 upregulated miRNAs in tumor tissue (GBM-T) versus adjacent normal tissue (GBM-N). Supplementary Table S5. The correlation between miR-663 expression and clinicopathological factors of patients with astrocytoma (Grade I and II). Supplementary Table S6. The correlation between miR-663 expression and clinicopathological factors of patients with anaplastic astrocytoma (Grade III). Supplementary Table S7. The correlation between miR-663 expression and clinicopathological factors of patients with GBM (Grade IV). Supplementary Table S8. Univariate analysis for disease-free survival and overall survival in GBM patients. Supplementary Table S9. Top 30 overlapped predicted targets of miR-663 and their degrees based on signal transduction network.
Supplementary Methods, Figure Legends from Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting PIK3CD and Predicts the Prognosis of Human Glioblastoma
Authors: Shi Yu , Chen Cong , Zhang Xia , Liu Qing , Xu Jin-Ling , Zhang Hua-Rong , Yao Xiao-Hong , Jiang Tao , He Zhi-Cheng , Ren Yong , Cui Wei , Xu Chuan , Liu Ling , Cui You-Hong , Yu Shi-Zhu , Ping Yi-Fang , Bian Xiu-Wu
Published: April 2023

PDF file - 138K
Supplementary Figure 1 from Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting PIK3CD and Predicts the Prognosis of Human Glioblastoma
Authors: Shi Yu , Chen Cong , Zhang Xia , Liu Qing , Xu Jin-Ling , Zhang Hua-Rong , Yao Xiao-Hong , Jiang Tao , He Zhi-Cheng , Ren Yong , Cui Wei , Xu Chuan , Liu Ling , Cui You-Hong , Yu Shi-Zhu , Ping Yi-Fang , Bian Xiu-Wu
Published: April 2023

PDF file - 455K, Supplementary Fig. S1. The prognostic values of miR-663 in GBM patients stratified by IDH1/ATRX status.
Supplementary Methods from Alternative Cleavage and Polyadenylation during Colorectal Cancer Development
Authors: Morris Adam R. , Bos Arnold , Diosdado Begoña , Rooijers Koos , Elkon Ran , Bolijn Anne S. , Carvalho Beatriz , Meijer Gerrit A. , Agami Reuven
Published: April 2023

PDF file - 68K
Supplementary Figure 2 from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
Authors: Win Thida , Miles Kenneth A. , Janes Sam M. , Ganeshan Balaji , Shastry Manu , Endozo Raymondo , Meagher Marie , Shortman Robert I. , Wan Simon , Kayani Irfan , Ell Peter J. , Groves Ashley M.
Published: April 2023

Supplementary Figure 2 - PDF file 34K, Kaplan Meier curve (along with number of patients at risk for each group over time) showing the proportion of patients surviving for treatment in the validation data-set
Supplementary Data from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
Authors: Win Thida , Miles Kenneth A. , Janes Sam M. , Ganeshan Balaji , Shastry Manu , Endozo Raymondo , Meagher Marie , Shortman Robert I. , Wan Simon , Kayani Irfan , Ell Peter J. , Groves Ashley M.
Published: April 2023

Supplementary Data from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
Supplementary Methods and Materials from Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
Authors: Sanford Dominic E. , Belt Brian A. , Panni Roheena Z. , Mayer Allese , Deshpande Anjali D. , Carpenter Danielle , Mitchem Jonathan B. , Plambeck-Suess Stacey M. , Worley Lori A. , Goetz Brian D. , Wang-Gillam Andrea , Eberlein Timothy J. , Denardo David G. , Goedegebuure Simon Peter , Linehan David C.
Published: April 2023

PDF - 101K, Additional details of experiments performed in manuscript.
Supplementary Figure 6 from Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
Authors: Sanford Dominic E. , Belt Brian A. , Panni Roheena Z. , Mayer Allese , Deshpande Anjali D. , Carpenter Danielle , Mitchem Jonathan B. , Plambeck-Suess Stacey M. , Worley Lori A. , Goetz Brian D. , Wang-Gillam Andrea , Eberlein Timothy J. , Denardo David G. , Goedegebuure Simon Peter , Linehan David C.
Published: April 2023

PDF - 156K, Monocytes and macrophages are increased in the premetastatic livers of tumor bearing mice.
Supplementary Figure 2 from Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Authors: Flanigan Sara A. , Pitts Todd M. , Newton Timothy P. , Kulikowski Gillian N. , Tan Aik Choon , McManus Martine C. , Spreafico Anna , Kachaeva Maria I. , Selby Heather M. , Tentler John J. , Eckhardt S. Gail , Leong Stephen
Published: April 2023

Supplementary Figure 2 - PDF file 153K, Bar Graphs of CI Values
Supplementary Figure 4 from Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
Authors: Sanford Dominic E. , Belt Brian A. , Panni Roheena Z. , Mayer Allese , Deshpande Anjali D. , Carpenter Danielle , Mitchem Jonathan B. , Plambeck-Suess Stacey M. , Worley Lori A. , Goetz Brian D. , Wang-Gillam Andrea , Eberlein Timothy J. , Denardo David G. , Goedegebuure Simon Peter , Linehan David C.
Published: April 2023

PDF - 192K, CCR2i alters the immune infiltrate in murine PC.
Supplementary Figure 1 from Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Authors: Flanigan Sara A. , Pitts Todd M. , Newton Timothy P. , Kulikowski Gillian N. , Tan Aik Choon , McManus Martine C. , Spreafico Anna , Kachaeva Maria I. , Selby Heather M. , Tentler John J. , Eckhardt S. Gail , Leong Stephen
Published: April 2023

Supplementary Figure 1 - PDF file 110K, Single Agent Proliferation Curves
Supplementary Figure 2 from Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
Authors: Sanford Dominic E. , Belt Brian A. , Panni Roheena Z. , Mayer Allese , Deshpande Anjali D. , Carpenter Danielle , Mitchem Jonathan B. , Plambeck-Suess Stacey M. , Worley Lori A. , Goetz Brian D. , Wang-Gillam Andrea , Eberlein Timothy J. , Denardo David G. , Goedegebuure Simon Peter , Linehan David C.
Published: April 2023

PDF - 352K, Human pancreatic cancers upregulate CCL2 expression, and are infiltrated by abundant myeloid cells.
Supplementary Figure 1 from Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
Authors: Sanford Dominic E. , Belt Brian A. , Panni Roheena Z. , Mayer Allese , Deshpande Anjali D. , Carpenter Danielle , Mitchem Jonathan B. , Plambeck-Suess Stacey M. , Worley Lori A. , Goetz Brian D. , Wang-Gillam Andrea , Eberlein Timothy J. , Denardo David G. , Goedegebuure Simon Peter , Linehan David C.
Published: April 2023

PDF - 99K, Monocytes are increased in the peripheral blood of pancreatic cancer patients.
Supplementary Tables 1 - 3 from Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
Authors: Imamura Yu , Morikawa Teppei , Liao Xiaoyun , Lochhead Paul , Kuchiba Aya , Yamauchi Mai , Qian Zhi Rong , Nishihara Reiko , Meyerhardt Jeffrey A. , Haigis Kevin M. , Fuchs Charles S. , Ogino Shuji
Published: April 2023

PDF file, 75K, Supplementary Table 1 shows characteristics of 1075 BRAF-wild-type cases. Supplementary Table 2 shows survival analysis limited to known stage I-IV cases. Supplementary Table 3 shows survival analysis including BRAF-mutated cases (total N=1255).
Supplementary Table S3 from Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome
Authors: Karlsson Anna , Jönsson Mats , Lauss Martin , Brunnström Hans , Jönsson Per , Borg Åke , Jönsson Göran , Ringnér Markus , Planck Maria , Staaf Johan
Published: April 2023

Supplementary Table S3. Table describing the functional analysis of differentially expressed genes between DNA methylation subgroups in the discovery and TCGA cohorts.
Supplementary Document 2 from Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
Authors: Fjeldbo Christina S. , Julin Cathinka H. , Lando Malin , Forsberg Malin F. , Aarnes Eva-Katrine , Alsner Jan , Kristensen Gunnar B. , Malinen Eirik , Lyng Heidi
Published: April 2023

Transformation of data from Illumina HT-12 and RT-qPCR assays to Illumina WG-6 scale.
Supplementary table 2 from Intratumor Heterogeneity in Hepatocellular Carcinoma
Authors: Friemel Juliane , Rechsteiner Markus , Frick Lukas , Böhm Friederike , Struckmann Kirsten , Egger Michèle , Moch Holger , Heikenwalder Mathias , Weber Achim
Published: April 2023

Supplementary table 2. Immune phenotypes of morphological defined Tumor areas
Supplementary Table 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
Authors: Nair Smita K. , De Leon Gabriel , Boczkowski David , Schmittling Robert , Xie Weihua , Staats Janet , Liu Rebecca , Johnson Laura A. , Weinhold Kent , Archer Gary E. , Sampson John H. , Mitchell Duane A.
Published: April 2023

PDF file - 47KB, Patient characteristics.
Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1
Authors: Heuck Christoph J. , Szymonifka Jackie , Hansen Emily , Shaughnessy John D. , Usmani Saad Z. , van Rhee Frits , Anaissie Elias , Nair Bijay , Waheed Sarah , Alsayed Yazan , Petty Nathan , Bailey Clyde , Epstein Joshua , Hoering Antje , Crowley John , Barlogie Bart
Published: April 2023

PDF file, 56K, Salvage Regimen for 255 Patients with available data.
Supplementary Figure 3 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
Authors: Nair Smita K. , De Leon Gabriel , Boczkowski David , Schmittling Robert , Xie Weihua , Staats Janet , Liu Rebecca , Johnson Laura A. , Weinhold Kent , Archer Gary E. , Sampson John H. , Mitchell Duane A.
Published: April 2023

PDF file - 69KB, Cytokine secretion analysis of CMV pp65-specific T cells co-cultured with primary GBM tumor cells.
Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1
Authors: Heuck Christoph J. , Szymonifka Jackie , Hansen Emily , Shaughnessy John D. , Usmani Saad Z. , van Rhee Frits , Anaissie Elias , Nair Bijay , Waheed Sarah , Alsayed Yazan , Petty Nathan , Bailey Clyde , Epstein Joshua , Hoering Antje , Crowley John , Barlogie Bart
Published: April 2023

PDF file, 142K, Effect of cumulative thalidomide dosing prior to start of maintence on OS and PFS, landmarked at start of maintence, for all patients.
Figure S4 from Interobserver Agreement in Describing the Ultrasound Appearance of Adnexal Masses and in Calculating the Risk of Malignancy Using Logistic Regression Models
Authors: Sladkevicius Povilas , Valentin Lil
Published: April 2023

Figure S4. Relationship between number of days between the two examinations and inter-observer difference in mean diameter of the largest solid component in benign and malignant tumors is shown on this scatterplot
Supplementary Table 3 from Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma
Authors: Zelba Henning , Weide Benjamin , Martens Alexander , Derhovanessian Evelyna , Bailur Jithendra Kini , Kyzirakos Christina , Pflugfelder Annette , Eigentler Thomas K. , Di Giacomo Anna Maria , Maio Michele , Aarntzen Erik H.J.G. , de Vries Jolanda , Sucker Antje , Schadendorf Dirk , Büttner Petra , Garbe Claus , Pawelec Graham
Published: April 2023

PDF file - 65K, Summarized percentages of cytokine-producing cells within the CD4 and CD8 compartment respectively for patients with antigen-specific T-cells.
Data Supplement from Sonic Hedgehog Paracrine Signaling Activates Stromal Cells to Promote Perineural Invasion in Pancreatic Cancer
Authors: Li Xuqi , Wang Zheng , Ma Qingyong , Xu Qinhong , Liu Han , Duan Wanxing , Lei Jianjun , Ma Jiguang , Wang Xiu , Lv Shifang , Han Liang , Li Wei , Guo Jian , Guo Kun , Zhang Dong , Wu Erxi , Xie Keping
Published: April 2023

Supplementary Figure 2.Illustrations of the co-culture model in vitro.
Supplementary Table 2 from Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma
Authors: Zelba Henning , Weide Benjamin , Martens Alexander , Derhovanessian Evelyna , Bailur Jithendra Kini , Kyzirakos Christina , Pflugfelder Annette , Eigentler Thomas K. , Di Giacomo Anna Maria , Maio Michele , Aarntzen Erik H.J.G. , de Vries Jolanda , Sucker Antje , Schadendorf Dirk , Büttner Petra , Garbe Claus , Pawelec Graham
Published: April 2023

PDF file - 43K, Univariate analysis using an alternative follow-up time, calculated from the date of diagnosed stage IV disease to the date of last follow-up or death.
Data Supplement from Sonic Hedgehog Paracrine Signaling Activates Stromal Cells to Promote Perineural Invasion in Pancreatic Cancer
Authors: Li Xuqi , Wang Zheng , Ma Qingyong , Xu Qinhong , Liu Han , Duan Wanxing , Lei Jianjun , Ma Jiguang , Wang Xiu , Lv Shifang , Han Liang , Li Wei , Guo Jian , Guo Kun , Zhang Dong , Wu Erxi , Xie Keping
Published: April 2023

Supplementary Figure 3.Expression of Sonic Hedgehog (SHH) in pancreatic carcinoma cells and tissues.
Supplementary Figure 2 from Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma
Authors: Zelba Henning , Weide Benjamin , Martens Alexander , Derhovanessian Evelyna , Bailur Jithendra Kini , Kyzirakos Christina , Pflugfelder Annette , Eigentler Thomas K. , Di Giacomo Anna Maria , Maio Michele , Aarntzen Erik H.J.G. , de Vries Jolanda , Sucker Antje , Schadendorf Dirk , Büttner Petra , Garbe Claus , Pawelec Graham
Published: April 2023

PDF file - 165K, Type of cytokines produced upon antigen stimulation. Proportion of patients with T-cells producing different cytokines in the group of all patients with detectable T-cells responding to NY-ESO-1, Melan-A or Influenza. CD4 (A) and CD8 (B) responses.
Supplementary Table 5 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
Authors: Beltran Pedro J. , Calzone Frank J. , Mitchell Petia , Chung Young-Ah , Cajulis Elaina , Moody Gordon , Belmontes Brian , Li Chi-Ming , Vonderfecht Steven , Velculescu Victor E. , Yang Guorong , Qi Jingwei , Slamon Dennis J. , Konecny Gottfried E.
Published: April 2023

PDF file - 53KB, IGF1R and INSR signaling in OV-90 and TOV-21G cell lines.
Supplemental Figure S2 from A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy
Authors: Saridaki Zenia , Weidhaas Joanne B. , Lenz Heinz-Josef , Laurent-Puig Pierre , Jacobs Bart , De Schutter Jef , De Roock Wendy , Salzman David W. , Zhang Wu , Yang Dongyun , Pilati Camilla , Bouché Olivier , Piessevaux Hubert , Tejpar Sabine
Published: April 2023

(A) Median progression-free survival according to type of therapy in the KRAS and BRAF mutated KRAS 3'-UTR LCS6 SNP carriers, (B) Median progression-free survival according to type of therapy in the KRAS and BRAF mutated non-KRAS 3'-UTR LCS6 SNP carriers, (C) Median overall survival according to type of therapy in the KRAS and BRAF mutated KRAS 3'-UTR LCS6 SNP carriers, (D) Median overall survival according to type of therapy in the KRAS and BRAF mutated non-KRAS 3'-UTR LCS6 SNP carriers.
Supplementary Tables 1 - 2 from Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects
Authors: Yoo Ji Young , Hurwitz Brian S. , Bolyard Chelsea , Yu Jun-Ge , Zhang Jianying , Selvendiran Karuppaiyah , Rath Kellie S. , He Shun , Bailey Zachary , Eaves David , Cripe Timothy P. , Parris Deborah S. , Caligiuri Michael A. , Yu Jianhua , Old Matthew , Kaur Balveen
Published: April 2023

PDF file - 164KB, Supplementary Table S1. Median-effect doses of bortezomib and oHSV (34.5ENVE) in vitro. Supplementary Table S2. Statistical analysis of viral replication data. Data shown are the fold increase in virus replication after bortezomib treatment of the indicated cells.
Supplementary Methods, Tables 1 - 4, Figure Legends from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Authors: Di Cosimo Serena , Sathyanarayanan Sriram , Bendell Johanna C. , Cervantes Andrés , Stein Mark N. , Braña Irene , Roda Desamparados , Haines Brian B. , Zhang Theresa , Winter Christopher G. , Jha Sharda , Xu Youyuan , Frazier Jason , Klinghoffer Richard A. , Leighton-Swayze Ann , Song Yang , Ebbinghaus Scot , Baselga José
Published: April 2023

Supplementary Table 1. Hits from the dalotuzumab enhancer screen. Supplementary Table 2. Patient and disease characteristics. Supplementary Table 3. Summary of dose-limiting toxicities. Supplementary Table 4. Summary of clinical efficacy in breast cancer patients.
Supplementary Figure 1 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Authors: Di Cosimo Serena , Sathyanarayanan Sriram , Bendell Johanna C. , Cervantes Andrés , Stein Mark N. , Braña Irene , Roda Desamparados , Haines Brian B. , Zhang Theresa , Winter Christopher G. , Jha Sharda , Xu Youyuan , Frazier Jason , Klinghoffer Richard A. , Leighton-Swayze Ann , Song Yang , Ebbinghaus Scot , Baselga José
Published: April 2023

Supplementary Figure 1. Treatment and pharmacodynamic assessment schedules.
Data Supplement from Demethylating Drugs as Novel Analgesics for Cancer Pain
Authors: Viet Chi T. , Dang Dongmin , Ye Yi , Ono Kentaro , Campbell Ronald R. , Schmidt Brian L.
Published: April 2023

Supplementary Supplementary Table S1. Patient demographics and tumor characteristics and staging. Supplementary Table S2. Mean methylation value comparisons between normal vs. SCC and dysplasia vs. SCC. Supplementary Table S3. Statistical analyses of presented data.
Supplementary table 3 from WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy
Authors: Bosch Linda J.W. , Luo Yanxin , Lao Victoria V. , Snaebjornsson Petur , Trooskens Geert , Vlassenbroeck Ilse , Mongera Sandra , Tang Weiliang , Welcsh Piri , Herman James G. , Koopman Miriam , Nagtegaal Iris D. , Punt Cornelis J.A. , van Criekinge Wim , Meijer Gerrit A. , Monnat Raymond J. , Carvalho Beatriz , Grady William M.
Published: April 2023

Primer sequences used for WRN promoter region MSP and bisulfite sequencing assays
Supplementary Table 5 from Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal Cancer
Authors: Stevenson Leanne , Allen Wendy L. , Turkington Richard , Jithesh Puthen V. , Proutski Irina , Stewart Gail , Lenz Heinz-Josef , Van Schaeybroeck Sandra , Longley Daniel B. , Johnston Patrick G.
Published: April 2023

PDF file - 145K, siRNA/chemo interaction P values
Data Supplement from Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations
Authors: Zimmer Lisa , Barlesi Fabrice , Martinez-Garcia Maria , Dieras Veronique , Schellens Jan H.M. , Spano Jean-Philippe , Middleton Mark R. , Calvo Emiliano , Paz-Ares Luiz , Larkin James , Pacey Simon , Venturi Miro , Kraeber-Bodéré Françoise , Tessier Jean J.L. , Eberhardt Wilfried Ernst Erich , Paques Michel , Guarin Ernesto , Meresse Valerie , Soria Jean-Charles
Published: April 2023

Supplementary Figure 1. Mutation panel (OncoCarta panel v.1.0) tested in phase 1 expansion study (19 oncogenes and 225 mutations)
Supplementary Table 1 from Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal Cancer
Authors: Stevenson Leanne , Allen Wendy L. , Turkington Richard , Jithesh Puthen V. , Proutski Irina , Stewart Gail , Lenz Heinz-Josef , Van Schaeybroeck Sandra , Longley Daniel B. , Johnston Patrick G.
Published: April 2023

PDF file - 544K, In vitro and clinical microarray genelists
Supplementary Figure 3 from c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met
Authors: Stabile Laura P. , He Guoqing , Lui Vivian Wai Yan , Thomas Sufi M. , Henry Cassandra , Gubish Christopher T. , Joyce Sonali , Quesnelle Kelly M. , Siegfried Jill M. , Grandis Jennifer R.
Published: April 2023

PDF file - 473K, Phospho-Met immunohistochemistry from representative VC-2 and DA-Src-5 tumor xenografts. Quantitative data of 5 samples from each treatment group. P<0.0001.
Supplementary Figure 2 from c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met
Authors: Stabile Laura P. , He Guoqing , Lui Vivian Wai Yan , Thomas Sufi M. , Henry Cassandra , Gubish Christopher T. , Joyce Sonali , Quesnelle Kelly M. , Siegfried Jill M. , Grandis Jennifer R.
Published: April 2023

PDF file - 36K, After 48 hrs of incubation, the conditioned media was harvested from normal lung fibroblasts (NLFB, positive control), 201T lung tumor cells (negative control), VC-2, and DA-Src-5 cell lines. Each conditioned medium sample was concentrated from 4ml to 500μl. ELISA was performed with the Quantikine� Immunoassay Kit of human HGF. HGF concentration in the media was normalized to its respective protein concentration from total cell lysates. Each reaction was performed in triplicate.
Supplementary Figure 1 from c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met
Authors: Stabile Laura P. , He Guoqing , Lui Vivian Wai Yan , Thomas Sufi M. , Henry Cassandra , Gubish Christopher T. , Joyce Sonali , Quesnelle Kelly M. , Siegfried Jill M. , Grandis Jennifer R.
Published: April 2023

PDF file - 31K, DA-Src cells and VC cells had similar sensitivity towards cisplatin treatment. Cells were treated with cisplatin (0.1μM, 1.0μM and 5.0μM) for 72 hrs, followed by MTT assay. Cumulative data from 3 independent experiments are shown. No statistical significant difference was observed at any dose between the VC and DA-Src groups (P>0.1, ns.).
Supplemental Table S2 from A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma
Authors: Saito Motonobu , Shiraishi Kouya , Matsumoto Kenji , Schetter Aaron J. , Ogata-Kawata Hiroko , Tsuchiya Naoto , Kunitoh Hideo , Nokihara Hiroshi , Watanabe Shun-ichi , Tsuta Koji , Kumamoto Kensuke , Takenoshita Seiichi , Yokota Jun , Harris Curtis C. , Kohno Takashi
Published: April 2023

Differentially expressed 59 miRNAs between responders and nonresponders.
Supplemental Figure S4 from A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma
Authors: Saito Motonobu , Shiraishi Kouya , Matsumoto Kenji , Schetter Aaron J. , Ogata-Kawata Hiroko , Tsuchiya Naoto , Kunitoh Hideo , Nokihara Hiroshi , Watanabe Shun-ichi , Tsuta Koji , Kumamoto Kensuke , Takenoshita Seiichi , Yokota Jun , Harris Curtis C. , Kohno Takashi
Published: April 2023

Progression-free survival of responders (R) and non-responders (NR) in all subjects (combined test and validation cohorts).
Supplemental Figure S3 from A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma
Authors: Saito Motonobu , Shiraishi Kouya , Matsumoto Kenji , Schetter Aaron J. , Ogata-Kawata Hiroko , Tsuchiya Naoto , Kunitoh Hideo , Nokihara Hiroshi , Watanabe Shun-ichi , Tsuta Koji , Kumamoto Kensuke , Takenoshita Seiichi , Yokota Jun , Harris Curtis C. , Kohno Takashi
Published: April 2023

Receiver operating characteristics (ROC) analysis was performed for miR-1290, miR-196b, and miR-135a* in the validation cohort.
Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Authors: Srivastava Raghvendra M. , Lee Steve C. , Andrade Filho Pedro A. , Lord Christopher A. , Jie Hyun-Bae , Davidson H. Carter , López-Albaitero Andrés , Gibson Sandra P. , Gooding William E. , Ferrone Soldano , Ferris Robert L.
Published: April 2023

PDF file - 441K, Importance of IFN-γ released by cetuximab activated NK cells in the enhancement of DC maturation.
Supplemental Figure S2 from A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma
Authors: Saito Motonobu , Shiraishi Kouya , Matsumoto Kenji , Schetter Aaron J. , Ogata-Kawata Hiroko , Tsuchiya Naoto , Kunitoh Hideo , Nokihara Hiroshi , Watanabe Shun-ichi , Tsuta Koji , Kumamoto Kensuke , Takenoshita Seiichi , Yokota Jun , Harris Curtis C. , Kohno Takashi
Published: April 2023

Expression of miRNAs in non-responders (NR) and responders (R) in the validation cohort as measured by qRT-PCR.
Supplementary Tables 1 - 4 from Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer
Authors: Singh Anand Kamal , Chandra Nishi , Bapat Sharmila A.
Published: April 2023

Supplementary Table 1. Differentially methylated genes in correlation with their expression pattern in the A4 progression model Supplementary Table 2. Genes enriched for different histone methylation marks in A4 progression model identified through ChIP-on-chip Supplementary Table 3. Expression analyses of genes enriched with mono-, bi- and trivalent K4, K9 and K27 marks in A4 progression model Supplementary Table 4. Differentially regulated genes associated exclusively with histone marks
Supplemental Table 1 from Prostate MRI: Evaluating Tumor Volume and Apparent Diffusion Coefficient as Surrogate Biomarkers for Predicting Tumor Gleason Score
Authors: Donati Olivio F. , Afaq Asim , Vargas Hebert Alberto , Mazaheri Yousef , Zheng Junting , Moskowitz Chaya S. , Hricak Hedvig , Akin Oguz
Published: April 2023

Patient Demographics.